FIELD: medicine.
SUBSTANCE: there are offered methods for inhibition of a cancer cell, methods of treating cancer with the use of a combination of myxoma virus or its analogue which expresses no functional M135R, and rapamycin, pharmaceutical compositions and kits containing the combination of myxoma virus or its analogue which expresses no functional M135R, and rapamycin. Rapamycin treatment enhances an ability of myxoma virus to infects the cells selectivity which are characterised by a deficient natural antiviral response, including the cells having no response on interferon.
EFFECT: inventions are applicable for treating malignancies with less toxic effect on intact cells.
76 cl, 43 dwg, 3 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATION OF MYXOMA VIRUS FOR THERAPEUTIC TREATMENT OF CANCER AND CHRONIC VIRUS INFECTION | 2004 |
|
RU2362584C2 |
| POLYPEPTIDE WITH ANTIVIRAL, ANTIPROLIFERATIVE AND/OR IMMUNOMODULATING ACTIVITIES, SEPARATED POLYNUCLEOTIDE | 2002 |
|
RU2328528C2 |
| ONCOLYTIC VIRUS FOR IMMUNOLOGIC CONTROL POINT MODULATORS EXPRESSION | 2015 |
|
RU2696312C2 |
| THERAPEUTIC COMPOSITIONS AND METHODS OF USING FOR TREATING CANCER | 2016 |
|
RU2720984C2 |
| M2-DEFECTIVE POXVIRUS | 2019 |
|
RU2819245C2 |
| COMBINATION OF ONCOLYTIC VIRUS WITH MODULATORS OF IMMUNOLOGICAL CONTROL POINTS | 2015 |
|
RU2705780C2 |
| USE OF GENETICALLY MODIFIED PATHOGENIC MEASLES VIRUS WITH IMPROVED APOPTOTIC PROPERTIES (MV-DELTAC VIRUS) IN CANCER THERAPY | 2014 |
|
RU2700083C2 |
| PREVENTIVE OR THERAPEUTIC AGENT AGAINST VIRAL DISEASE | 2007 |
|
RU2433827C2 |
| COATED ONCOLYTIC ADENOVIRUS FOR ANTICANCER VACCINES | 2015 |
|
RU2695375C2 |
| DOSING REGIME AND FORMULATIONS FOR TYPE B ADENOVIRUSES | 2014 |
|
RU2671558C2 |
